CMT Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-194,100
Closed -$17.2M 13
2017
Q3
$17.2M Sell
194,100
-31,200
-14% -$2.38M 0.83% 39
2017
Q2
$16.3M Buy
225,300
+109,800
+95% +$7.38M 1.09% 29
2017
Q1
$7.53M Buy
115,500
+34,200
+42% +$2.15M 0.64% 47
2016
Q4
$5.09M Sell
81,300
-37,400
-32% -$2.28M 0.24% 90
2016
Q3
$7.49M Buy
118,700
+105,000
+766% +$6.8M 0.34% 76
2016
Q2
$8.48M Sell
13,700
-63,900
-82% -$3.89M 0.43% 70
2016
Q1
$4.43M Sell
77,600
-28,500
-27% -$1.59M 0.3% 82
2015
Q4
$6.29M Buy
106,100
+18,100
+21% +$1.04M 0.32% 76
2015
Q3
$4.79M Buy
88,000
+59,100
+204% +$3.85M 0.27% 85
2015
Q2
$1.94M Buy
28,900
+3,900
+16% +$255K 0.12% 130
2015
Q1
$1.46M Buy
+25,000
New +$1.51M 0.11% 130

Other funds holding ABBV

CMT Asset Management's ABBV Position: Q4 2017 in Review

CMT Asset Management sold out of AbbVie (ABBV) in Q4 2017, closing a stake of 5,898 shares — an estimated $524K sold.

CMT Asset Management first reported a position in ABBV in Q1 2015 and held it in 8 quarters. The position peaked at $2.78M in Q3 2015. 2,000 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

  • CMT Asset Management reported no remaining AbbVie position as of Q4 2017 after selling out during the quarter.
  • CMT Asset Management sold 5,898 AbbVie shares in Q4 2017, an estimated $524K.
  • CMT Asset Management first reported a position in AbbVie in Q1 2015 and held it in 8 quarters.
  • CMT Asset Management's AbbVie position peaked at $2.78M in Q3 2015.
  • 2,000 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on CMT Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.